![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that...
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 3.33333333333 | 3 | 3.14 | 2.915 | 1075736 | 3.02395262 | CS |
4 | -0.26 | -7.7380952381 | 3.36 | 3.64 | 2.915 | 1068723 | 3.22338264 | CS |
12 | 0.17 | 5.80204778157 | 2.93 | 3.64 | 2.63 | 1149587 | 3.062098 | CS |
26 | 0.7 | 29.1666666667 | 2.4 | 3.64 | 2.21 | 1122331 | 2.86204524 | CS |
52 | 0.82 | 35.9649122807 | 2.28 | 3.64 | 1.69 | 875066 | 2.55677856 | CS |
156 | -0.71 | -18.6351706037 | 3.81 | 6.5 | 1.69 | 1898045 | 3.50388852 | CS |
260 | 0.84 | 37.1681415929 | 2.26 | 9 | 0.81 | 2079099 | 3.66895778 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions